• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    1/29/24 12:31:07 PM ET
    $BCEL
    $BFRG
    $CRBP
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCEL alert in real time by email

    Gainers

    • OneMedNet (NASDAQ:ONMD) shares increased by 175.1% to $1.41 during Monday's regular session. The company's market cap stands at $45.3 million.
    • Palisade Bio (NASDAQ:PALI) shares moved upwards by 106.48% to $1.07. The company's market cap stands at $9.9 million.
    • NexImmune (NASDAQ:NEXI) shares moved upwards by 84.48% to $9.87. The market value of their outstanding shares is at $10.4 million.
    • FibroGen (NASDAQ:FGEN) shares rose 54.93% to $1.45. The market value of their outstanding shares is at $142.5 million.
    • Atreca (NASDAQ:BCEL) shares rose 42.09% to $0.35. The company's market cap stands at $13.8 million.
    • Vivos Therapeutics (NASDAQ:VVOS) stock increased by 27.22% to $6.87. The market value of their outstanding shares is at $9.1 million.

    Losers

    • Panbela Therapeutics (NASDAQ:PBLA) shares decreased by 67.2% to $1.4 during Monday's regular session.
    • Processa Pharma (NASDAQ:PCSA) stock fell 29.98% to $2.57. The company's market cap stands at $3.1 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) stock fell 24.29% to $5.33. The market value of their outstanding shares is at $32.4 million.
    • Inspire Veterinary (NASDAQ:IVP) stock declined by 23.31% to $0.17. The market value of their outstanding shares is at $1.8 million.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) shares fell 19.03% to $23.88. The market value of their outstanding shares is at $105.6 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock declined by 19.02% to $1.15. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCEL
    $BFRG
    $CRBP
    $FGEN

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2025$28.00Buy
    B. Riley Securities
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    2/28/2025Outperform
    William Blair
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    12/2/2024Overweight
    Piper Sandler
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2024$85.00Outperform
    Wedbush
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/22/2024$80.00Buy
    H.C. Wainwright
    More analyst ratings

    $BCEL
    $BFRG
    $CRBP
    $FGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BCEL
    $BFRG
    $CRBP
    $FGEN
    SEC Filings

    View All

    SEC Form 10-K filed by Corbus Pharmaceuticals Holdings Inc.

    10-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    3/9/26 4:16:00 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    3/9/26 7:43:03 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    2/25/26 7:45:30 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    $BFRG
    $CRBP
    $FGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Smethurst Dominic sold $50,601 worth of shares (6,097 units at $8.30), decreasing direct ownership by 6% to 89,790 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    3/4/26 4:30:18 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hodgson Ian sold $6,253 worth of shares (847 units at $7.38), decreasing direct ownership by 2% to 51,080 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/18/26 4:32:02 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Moran Sean F. sold $36,588 worth of shares (4,701 units at $7.78), decreasing direct ownership by 5% to 96,694 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/18/26 4:31:03 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    $BFRG
    $CRBP
    $FGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCEL
    $BFRG
    $CRBP
    $FGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

    3/9/26 7:00:00 AM ET
    $FGEN
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Announces Participation in Two Upcoming Investor Conferences

    Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care ConferenceDate/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation & investor meetingsWebcast link: Register here Investors registered to attend the conference who wish t

    3/2/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

    MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet's position for life sciences and healthcare organizations generati

    2/27/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BCEL
    $BFRG
    $CRBP
    $FGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCEL
    $BFRG
    $CRBP
    $FGEN
    Financials

    Live finance-specific insights

    View All

    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

    3/9/26 7:00:00 AM ET
    $FGEN
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

    CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending d

    12/11/25 7:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

    NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced the Company's plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December 11, 2025. Corbus will host a conference call and live webcast the same day at 8:00 am ET to review and discuss the Phase 1a data. To register for the webcast, click here . A replay will be available on the Corbus website. About CRB-913CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (

    12/10/25 4:01:00 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCEL
    $BFRG
    $CRBP
    $FGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/14/24 4:52:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care